Skip to content
    ICLR
    Earnings call· Mar 2026(Q1 FY26)

    ICON Q1 FY26 earnings call ICLR

    Jun 24, 2026 Source

    Executive summary

    ICON plc Q1 FY26 — Strong Bookings & Reaffirmed Guidance

    ICON plc delivered Q1 FY26 results in line with expectations, driven by strong commercial execution and robust bookings, which saw net business wins increase 42% year-over-year. Despite a constant currency revenue decline and gross margin pressure from prior demand dynamics and mix shifts, the company reaffirmed its full-year guidance. Management is focused on strategic investments in labs and digital innovation, alongside disciplined cost management, to drive sequential margin improvement and long-term growth.

    Highlights

    5

    • Gross bookings reached $3.3 billion, an increase of 22% year-over-year.

    • Net business wins were $2.88 billion, up 42% year-over-year, resulting in a net book-to-bill of 1.42x.

    • Adjusted EBITDA margin increased 10 basis points sequentially to 15.6%.

    • Secured a Central Labs partnership from a top 5 pharma customer, expanding service offerings.

    • Sustained strong win rates in both large pharma and biotech full service segments.

    Concerns

    4

    • Revenue decreased 1.9% on a constant currency basis due to challenging prior demand dynamics.

    • Adjusted gross margin declined to 24.4% from 28.4% in Q1 2025.

    • Cancellations, though low at $383 million in Q1, are expected to run higher in future quarters, potentially $500 million-$600 million.

    • Full-year 2026 EBITDA is forecasted to be about $200 million lower than last year.

    Guidance & targets

    10
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $7.85 billion to $8.15 billion
    high materiality
    High
    Full-year 2026 Adjusted Diluted Earnings Per Share
    $10 to $11
    high materiality
    High
    Full-year 2026 Adjusted Effective Tax Rate
    approximately 17%
    medium materiality
    High
    Q2 FY26 Adjusted EBITDA Margin
    around 16%
    medium materiality
    Medium
    Full-year 2026 EBITDA
    about $200 million lower than last year
    high materiality
    High
    Book-to-bill assumption
    somewhere around 1.0
    medium materiality
    Medium
    Pass-throughs
    broadly stable at that Q1 level
    medium materiality
    Medium
    Q2 FY26 Free Cash Flow
    generally lower than Q1
    low materiality
    High
    Share Buybacks
    able to go back to start buybacks again
    medium materiality
    High
    Direct Fee Book-to-Bill
    stay open the 1.2x territory
    low materiality
    Medium

    Operational metrics

    13
    Gross bookings
    $3.3 billionup 22% year-over-year
    Q1 FY26

    Matched strong performance in Q4 2025.

    Cancellations
    $383 million
    Q1 FY26

    In line with improved levels seen in Q4 2025; notably low, future run rate expected to be higher, potentially $500M-$600M.

    Net business wins
    $2.88 billionincrease of 42% year-over-year
    Q1 FY26

    Resulted from strong gross bookings and low cancellations.

    Net book-to-bill
    1.42x
    Q1 FY26

    Reflects strong bookings performance.

    Direct fee book-to-bill
    in excess of 1.3x
    Q1 FY26

    Solid contribution of direct fee versus pass-through awards.

    RFP flow (biotech full service)
    increased low double digitssequentially
    Q1 FY26

    Particularly strong RFP flow also seen in Pharma full service and Development Solutions.

    RFP flow (midsize pharma)
    up high teensyear-over-year
    Q1 FY26

    Opportunity flow improving in this segment.

    Customer concentration (Top 5)
    25%
    Q1 FY26

    Percentage of total revenue from top 5 customers, aligned with Q4 2025.

    Customer concentration (Top 10)
    40.3%
    Q1 FY26

    Percentage of total revenue from top 10 customers.

    Customer concentration (Top 25)
    63.4%
    Q1 FY26

    Percentage of total revenue from top 25 customers.

    US counties lacking active oncology trials
    70%
    Current

    Highlights the concentration of trial access and patient recruitment challenges in oncology research.

    Phase III trials in Q2 awards
    up around 38%, 39%average SKUs from 29% to 45%
    Q2 FY26 (expected)

    Expected increase in the number of Phase III trials in Q2 awards, indicating a positive mix shift.

    Ballparks as % of RFPs
    17%bounced from about 12% in Q4
    Q1 FY26

    Ballparks skew heavily towards development solutions business; expected to tick up in Q2 for biotech.

    Industry KPIs

    4
    MetricValueDetails
    Revenue EPS guidanceRevenue $7.85B-$8.15B; Adjusted EPS $10-$11USD
    Pricing price realizationNo change
    Clinical research cro bookings$3.3 billionUSD
    End market demand funnel commentaryPositive

    Deals & partnerships

    4
    Top 5 pharma customercustomer contract

    Award of a Central Labs partnership from a top 5 pharma customer, where ICON had limited Labs business in the past. Cited factors included flexibility, strong project management, kit operation strategy, and long-standing delivery in other functions.

    Incumbent large CRO provider (displaced)customer contract

    Secured a new midsized partnership, displacing an incumbent large CRO provider. ICON's global execution capabilities, commitment to strategic collaboration, and focus on digital innovation were central to securing this partnership.

    Brian-Miran Cancer Institutepartnership

    Expanded oncology research capabilities through a partnership with the Brian-Miran Cancer Institute in the U.S. This establishes a flagship oncology site to address patient recruitment challenges and expand patient access to cancer therapies.

    Microsoftpartnership

    Partnership to evolve ICON's digital architecture to an intelligence-led platform. Focus areas include developing the 'Argus' Agentic AI platform, enterprise-wide deployment of Copilot for efficiency, and developing domain-specific AI agents embedded in clinical development workflows.

    Risks & headwinds

    5
    Revenue decline on constant currency basisQ1 FY26

    1.9% decrease

    Mitigation: Commercial strategy delivering increased full-service direct fee revenue and disciplined cost management.

    Adjusted gross margin declineQ1 FY26 vs Q1 FY25

    400 bps decrease (24.4% vs 28.4% in Q1 2025)

    Mitigation: Modest sequential margin improvement throughout the year, driven by increased full-service direct fee revenue and disciplined cost management.

    Higher cancellation run rateFuture quarters

    Potentially $500 million-$600 million (vs $383 million in Q1 FY26)

    Mitigation: Focus on converting demand into high-quality, profitable revenue.

    EBITDA forecasted lower year-over-yearFull year 2026

    $200 million lower

    Mitigation: Focus on margin dollar gradual improvement, mitigating mix impacts, and cost actions.

    Margin pressure from mix shifts, FX, and pricing dynamicsQ1 FY26

    Contributed to gross margin decline

    Mitigation: Commercial strategy delivering increased full-service direct fee revenue and disciplined cost management.

    Q&A highlights

    8

    Why did the spread between backlog and performance obligations widen, and is it due to new awards not yet contracted or adjustments to contracted awards?

    The widening spread is due to strong book-to-bill (new awards not yet contracted) and Q1 being seasonally weaker for signings. Q2 is expected to be a very strong quarter for signings, which should shift this number.

    “It's two things. As you rightly say, it's strong book-to-bill right back to back. So you're going to see some drag there. The other side of it is seasonality-wise, Q1 is not always the strongest quarter for signings. I will tell you that Q2 is looking like a very strong quarter for signings. So I'd expect a significant shift in that number in the Q2 print.”

    asked by Eric Coldwell · answered by Barry Balfe

    2 min read5 chapters

    Detailed Narrative

    01

    Commercial Excellence & Diversification

    ICON's focus on commercial excellence has led to significant progress in diversifying sales channels in large pharma, expanding in the midsize segment, and increasing RFP flow and win rates in biotech. This strategy is resonating with customers, as evidenced by a new Central Labs partnership with a top 5 pharma customer and a new midsized partnership displacing an incumbent CRO. The company's capacity to hybridize FSL and FSP models is central to its value proposition, meeting customer needs for seamless interoperability.

    02

    Strategic Investments for Growth

    The company is making targeted investments to support growth, including expanding its central laboratory facility in Singapore to enhance laboratory offerings and accelerate growth in Asia. Additionally, ICON expanded its oncology research capabilities through a partnership with the Brian-Miran Cancer Institute in the U.S. to address patient recruitment challenges. This initiative aims to expand patient access to cancer therapies, particularly given that nearly 70% of U.S. counties lack active oncology trials.

    03

    Digital Innovation & AI Platform

    ICON is evolving its digital architecture to an intelligence-led platform through a recently announced partnership with Microsoft. This collaboration focuses on three key strategic priorities: developing the 'Argus' Agentic AI platform to connect expertise, data, and AI across the trial lifecycle; deploying Copilot enterprise-wide to drive efficiency and automate repetitive tasks; and developing best-in-class domain-specific AI agents embedded directly into clinical development workflows.

    04

    Market Environment & Pipeline Quality

    The macro demand environment remains constructive, with ongoing biotech funding supporting late-stage clinical programs and large pharma continuing to invest in clinical pipelines. ICON is focused on converting high-quality opportunities into profitable revenue, employing a qualitative approach to pipeline assessment that emphasizes convertibility, pricing, and mix. The company noted a skew towards Phase III trials in recent awards and sustained strong win rates in biotech.

    05

    Margin Trajectory & Cost Management

    Despite current margin pressures from organic revenue decline, mix shifts (functional versus full service), foreign exchange, and pricing dynamics, ICON anticipates modest sequential margin improvement throughout the year. This trajectory is driven by actions already in flight, including increased full-service direct fee revenue as a proportion of the overall mix and disciplined cost management, with incremental benefits expected to flow more heavily in the second half of the year.

    AI-generated summary of the company’s earnings call. Not investment advice.